Post-traumatic Stress Disorder

Post-traumatic Stress Disorder Market Outlook

As of 2023, the global Post-traumatic Stress Disorder (PTSD) market is valued at approximately $9.5 billion, with a projected CAGR of around 6.3% from 2023 to 2030. This growth trajectory is driven by an increasing awareness of mental health issues and a significant rise in the incidence of PTSD due to factors such as military conflicts, natural disasters, and personal traumas. Additionally, the expansion of telehealth services and the integration of technology in therapy, including apps and online platforms, are facilitating better access to treatment options for individuals suffering from PTSD. The mental health stigma is gradually diminishing, leading to more individuals seeking help and utilizing available resources. The ongoing research and development of new therapeutic modalities and medications further contribute to the market's robust growth potential.

Growth Factor of the Market

The growth of the PTSD market can be attributed to several key factors. First and foremost is the increased global recognition of mental health issues, which has encouraged governments and organizations to allocate more resources towards mental health care, including PTSD treatment. Furthermore, advancements in therapy techniques, such as cognitive-behavioral therapy and exposure therapy, have proven effective in treating PTSD, thus expanding the market. The surge in veteran populations seeking mental health services, particularly in countries like the United States, has also significantly impacted market growth. Additionally, the development and availability of self-help tools and mobile applications offer innovative and accessible methods for managing PTSD symptoms. Lastly, the rising prevalence of natural disasters and traumatic events worldwide further escalates the need for effective PTSD interventions.

Key Highlights of the Market

• Increasing prevalence of PTSD among various demographics, notably military personnel and disaster survivors.
• Growth in telehealth services that provide convenient access to mental health care.
• Rising public and governmental awareness regarding mental health issues.
• Development of innovative self-help tools and applications.
• Expansion of clinical trials and research leading to new treatment options.

By Product Type

Medications :

Medications constitute a significant segment of the PTSD market, encompassing various pharmaceuticals designed to alleviate symptoms. Common classes of medications include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antipsychotics. These medications aim to balance neurotransmitters in the brain, leading to improved mood and reduced anxiety levels. The growing acceptance of pharmacological treatments, supported by clinical guidelines, has resulted in the increased prescription of these drugs for PTSD patients. Moreover, the ongoing research into new formulations and combinations is expected to enhance medication efficacy and safety, further driving market growth in this segment.

Therapy :

Therapy remains a cornerstone of PTSD treatment, providing patients with structured psychological interventions aimed at addressing trauma-related issues. Various therapeutic modalities, including cognitive-behavioral therapy (CBT), exposure therapy, and eye movement desensitization and reprocessing (EMDR), have shown significant efficacy in alleviating PTSD symptoms. The increasing recognition of the importance of psychotherapy in mental health care has spurred demand for trained professionals and established therapy frameworks. Additionally, the growing trend of integrating teletherapy services further supports access to therapeutic options, enabling patients to engage in treatment from the comfort of their homes. This shift is particularly beneficial for individuals hesitant to seek traditional in-person therapy due to stigma or logistical barriers.

Self-help Tools :

Self-help tools have emerged as a vital resource for individuals coping with PTSD, providing them with strategies to manage their symptoms independently. These tools can range from guided workbooks and audio programs to skill-building resources that educate individuals on coping mechanisms. The rise of self-help materials aligns with the increasing emphasis on patient empowerment and self-management in mental health care. These resources can be particularly useful for those who may not have immediate access to professional help or prefer more personalized approaches. The convenience and accessibility of self-help tools have garnered significant attention, making them an essential segment of the PTSD market.

Apps :

The proliferation of smartphones has led to a boom in mental health applications designed to support individuals with PTSD. These apps provide users with a variety of features, such as mood tracking, guided meditations, and coping strategies, allowing them to monitor their symptoms and access resources on-the-go. As more individuals turn to technology for mental health support, the market for PTSD-related apps continues to expand rapidly. Furthermore, many apps offer community features, enabling users to connect with others experiencing similar challenges, which can foster a sense of belonging and support. The ongoing development of evidence-based apps will likely drive further growth in this segment.

Others :

Within the PTSD market, various other products and interventions exist that do not neatly fit into the aforementioned categories. This segment includes educational materials, community support programs, workshops, and alternative therapies such as mindfulness and yoga. These resources aim to complement traditional treatments and provide holistic approaches to managing PTSD symptoms. The growing trend toward integrative mental health solutions has led to increased interest in these alternative approaches, contributing to overall market diversity. As awareness of diverse treatment options expands, this segment is anticipated to witness growth as individuals seek comprehensive strategies for addressing their trauma.

By Application

Military :

The military segment is one of the most prominent applications of PTSD treatment, as service members are disproportionately affected by trauma due to their experiences in combat and high-stress environments. The recognition of PTSD within military ranks has led to numerous initiatives aimed at improving mental health resources for active duty personnel and veterans. Specialized programs and services are increasingly being developed to address the unique challenges faced by military personnel, including stigma reduction campaigns and enhanced access to psychological care. Collaborative efforts between military organizations and healthcare providers contribute significantly to the advancement of effective PTSD treatment for this population.

Veterans :

Similarly, veterans represent a critical demographic in the PTSD market, as many experience long-term consequences of trauma sustained during their military service. The U.S. Department of Veterans Affairs (VA) and other organizations have established dedicated mental health programs aimed at providing comprehensive support specifically for veterans. These programs often incorporate evidence-based therapies alongside peer support networks to foster a supportive environment for recovery. The increasing advocacy for veterans' mental health has led to expanded funding and initiatives, aiming to reduce the barriers that veterans face in accessing PTSD treatment. As awareness continues to grow, the market dedicated to veteran applications is poised for continued expansion.

Emergency Services Personnel :

Emergency services personnel, including firefighters, police officers, and paramedics, often encounter traumatic events that can lead to PTSD. The high-stress nature of their jobs, combined with repeated exposure to trauma, necessitates specialized mental health resources tailored to their experiences. Initiatives aimed at supporting emergency responders have gained traction, focusing on building resilience and providing early intervention strategies. Efforts to destigmatize mental health issues within these professions have led to increased acceptance of seeking help, resulting in a growing demand for PTSD interventions specifically designed for emergency services personnel.

Survivors of Abuse :

Survivors of abuse constitute another crucial segment within the PTSD market, as many individuals who have experienced physical, emotional, or sexual trauma develop PTSD. The complexities surrounding trauma from abuse necessitate empathetic and specialized treatment approaches. Various programs and therapies are designed to address the unique needs of abuse survivors, emphasizing safety, empowerment, and recovery. The rising awareness of abuse and its long-term impacts has led to increased advocacy and funding for mental health services targeting this population. Consequently, the market for PTSD treatment focused on survivors of abuse is expanding as more individuals seek help.

Natural Disaster Survivors :

Natural disasters can result in widespread trauma, impacting communities and individuals alike. Survivors of hurricanes, earthquakes, wildfires, and other disasters often experience profound psychological effects, including PTSD. As the frequency and severity of natural disasters increase due to climate change, mental health resources are becoming increasingly vital. Community-based interventions focused on trauma recovery and resilience-building are emerging as essential components of disaster response efforts. The recognition of the psychological toll of natural disasters paves the way for an expanding market dedicated to supporting these survivors through effective PTSD treatment options.

By Distribution Channel

Hospitals :

Hospitals are a primary distribution channel for PTSD treatment, providing both inpatient and outpatient care to individuals suffering from severe symptoms. These medical facilities often house specialized mental health departments equipped with trained professionals capable of delivering comprehensive assessments and tailored treatment plans. The integration of mental health services within hospitals allows for a holistic approach to patient care, ensuring that both physical and psychological needs are addressed. As hospitals increasingly prioritize mental health resources, the demand for PTSD treatment through this channel is expected to grow, facilitated by collaborative care models.

Clinics :

Clinics serve as another crucial distribution channel for PTSD treatment, offering specialized outpatient services. These facilities often provide a range of therapeutic options, including individual and group therapy, medication management, and support groups. Many clinics focus on community-based care, allowing individuals to access services close to home, which can be particularly beneficial for those who may face barriers in reaching hospital settings. Furthermore, the increase in private mental health clinics has broadened the availability of PTSD treatment, catering to diverse patient populations and preferences.

Online Platforms :

Online platforms represent a rapidly growing distribution channel for PTSD treatment, leveraging technology to improve access to mental health resources. Telehealth services allow individuals to engage with trained therapists from the comfort of their homes, which can reduce barriers to care, such as transportation issues or social stigma. The convenience of online therapy, combined with the ability to access resources at any time, has made this channel increasingly popular among those seeking support for PTSD. As teletherapy continues to gain acceptance and credibility, the market for online platforms dedicated to PTSD treatment is likely to expand significantly.

Retail Pharmacies :

Retail pharmacies play a vital role in the distribution of PTSD medications, providing access to prescribed pharmaceuticals that are crucial for symptom management. These establishments serve as accessible points of care, often offering consultation services and medication counseling to patients. The increasing emphasis on mental health awareness has led to pharmacies expanding their mental health services, including educational materials related to PTSD. As more patients seek pharmacological interventions for their PTSD symptoms, retail pharmacies will continue to be an essential distribution channel.

Others :

The 'Others' category encompasses additional distribution channels that may include community organizations, support groups, and non-profit organizations providing mental health resources. These entities often facilitate workshops, peer support programs, and outreach initiatives aimed at raising awareness and providing treatment options for individuals with PTSD. The diversification of distribution channels reflects the growing recognition of the need for comprehensive support systems for mental health care. As these alternative channels become more prominent, they contribute meaningfully to the overall PTSD market.

By Ingredient Type

SSRIs :

Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed medications for PTSD, targeting the serotonergic system to improve mood and reduce anxiety. This class of antidepressants has been extensively studied and has shown effectiveness in alleviating PTSD symptoms, making them a first-line treatment option. SSRIs are particularly beneficial for individuals experiencing concurrent depression, as they address multiple mental health concerns. The growing acceptance of SSRIs, supported by clinical evidence and guidelines, has solidified their position in the PTSD market, driving demand within this ingredient type.

SNRIs :

Serotonin-norepinephrine reuptake inhibitors (SNRIs) are another class of medications utilized for the treatment of PTSD. These antidepressants work by increasing levels of both serotonin and norepinephrine in the brain, which can improve mood and reduce pain perception. SNRIs are particularly effective for individuals who might not respond adequately to SSRIs and are often prescribed as an alternative treatment option. The positive clinical outcomes associated with SNRIs, along with the growing recognition of the importance of personalized medicine, contribute to the expanding market for this ingredient type.

Atypical Antipsychotics :

Atypical antipsychotics are increasingly used in the management of PTSD, particularly for patients experiencing severe symptoms or co-occurring disorders such as anxiety or depression. These medications can help stabilize mood and address the cognitive symptoms associated with PTSD. The use of atypical antipsychotics often occurs in conjunction with psychotherapy, providing a comprehensive approach to treatment. As healthcare providers become more aware of the benefits of these agents, their incorporation into PTSD treatment plans is expected to rise, thereby expanding their presence in the market.

Antidepressants :

Antidepressants, including various classes such as tricyclic antidepressants, remain an essential component of the PTSD treatment landscape. While SSRIs and SNRIs are the most commonly prescribed, tricyclic antidepressants may be utilized in specific cases where other medications have proven ineffective. These medications work to alleviate depressive symptoms while also addressing anxiety, making them suitable for PTSD patients who present with varied symptom profiles. The continued exploration of antidepressants in PTSD treatment will likely result in sustained market activity within this ingredient type.

Others :

The 'Others' category includes alternative ingredients and compounds that may not fit within the traditional medication classes but still hold potential in PTSD treatment. This may encompass herbal supplements, vitamins, or experimental agents currently being studied for their therapeutic effects. As research in the field of mental health evolves, the exploration of these alternative ingredients may lead to the identification of novel treatment options. The growing interest in holistic and integrative approaches to mental health care supports the potential expansion of this segment within the PTSD market.

By Region

North America dominates the PTSD market, accounting for nearly 40% of the global market share. This is primarily due to the high incidence of PTSD among military veterans and the widespread availability of mental health resources in the region. The U.S. military's commitment to addressing PTSD, alongside the established healthcare infrastructure, facilitates access to treatment options for affected individuals. Moreover, the increasing emphasis on mental health awareness and the reduction of stigma surrounding mental health issues contribute to the region's robust market performance. The projected CAGR for this region is approximately 7.1%, driven by ongoing investments in mental health services.

Europe follows closely, holding approximately 30% of the global PTSD market share. The region benefits from a growing focus on mental health initiatives, with various countries implementing comprehensive strategies for PTSD awareness and treatment. The legislative support for mental health care, particularly in the UK and Germany, advances the accessibility of services for individuals suffering from PTSD. The integration of trauma-informed care into mental health systems enhances treatment efficacy, further fueling market growth. Additionally, the demand for alternative therapies and self-help resources is on the rise, contributing to the overall expansion of the PTSD market in Europe.

Opportunities

The PTSD market is rife with opportunities, particularly in the area of technological advancements. The rise of teletherapy and digital mental health platforms presents a unique chance to reach underserved populations, ensuring that individuals in remote or rural areas can access vital resources. As telehealth becomes more integrated into mainstream medical practices, the potential for increased patient engagement and adherence to treatment plans significantly improves. Moreover, the development of mobile applications focused on PTSD management allows for continuous support and monitoring, providing patients with tools to manage their symptoms effectively. This technology-driven approach fosters a shift toward personalized care, catering to the specific needs of individuals with PTSD.

Another opportunity lies in the growing awareness and education surrounding mental health issues. As public understanding of PTSD improves, individuals are more likely to seek help and access available treatments. This increased demand creates opportunities for healthcare providers and organizations to develop targeted programs and interventions designed to address the unique needs of diverse populations, including military personnel, disaster survivors, and abuse victims. Additionally, ongoing research into novel therapies and emerging treatment modalities, such as virtual reality exposure therapy, presents avenues for market expansion and innovation. By prioritizing education and awareness, stakeholders can harness these opportunities to enhance PTSD treatment accessibility and efficacy.

Threats

Despite the positive growth trajectory of the PTSD market, several threats could pose challenges to its expansion. One significant concern is the persistent stigma surrounding mental health issues, which can deter individuals from seeking help. Despite advances in awareness and education, societal perceptions of mental illness can lead to underreporting and inadequate treatment for those affected by PTSD. Additionally, budget constraints and funding cuts for mental health programs may hinder the availability of resources needed to support individuals in crisis. As a result, the market may face pressure from these societal and systemic factors that inhibit progress.

Another threat to the PTSD market is the potential for over-reliance on pharmacological treatments, which could overshadow the importance of psychotherapy and other complementary approaches. While medications play a crucial role in managing symptoms, they should ideally be used in conjunction with therapeutic interventions to address the root causes of PTSD. The risk of prioritizing quick fixes over comprehensive care may result in suboptimal treatment outcomes for patients. Ensuring a balanced approach that highlights the significance of both medication and therapy is vital for the long-term success of the market.

Competitor Outlook

• Pfizer Inc.
• Eli Lilly and Company
• Johnson & Johnson
• GlaxoSmithKline plc
• AbbVie Inc.
• Merck & Co., Inc.
• Boehringer Ingelheim
• AstraZeneca plc
• Otsuka Pharmaceutical Co., Ltd.
• H. Lundbeck A/S
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• NeuroRx, Inc.
• Mindstrong Health, Inc.

The competitive landscape of the PTSD market is characterized by a diverse array of stakeholders, ranging from pharmaceutical giants to innovative digital health companies. Major pharmaceutical companies, such as Pfizer and Eli Lilly, are actively involved in the development of medications that target PTSD symptoms. Their extensive research and development capabilities, coupled with established distribution channels, position them as key players in the market. These companies continuously invest in clinical trials to explore new formulations and treatment combinations, aiming to enhance the efficacy of existing therapies and address the evolving needs of patients.

In addition to traditional pharmaceutical companies, the rise of digital health solutions has introduced new competitors into the PTSD market. Companies like Mindstrong Health are pioneering the development of mental health apps and online platforms that facilitate accessible treatment options for individuals with PTSD. The integration of technology into mental health care is reshaping the competitive landscape, with new entrants leveraging data analytics and user-centric design to create innovative solutions that resonate with patients. As demand for teletherapy and digital resources grows, these companies are poised to capture a significant share of the market.

Furthermore, some companies focus on specialized treatment options tailored to specific populations, such as veterans or survivors of abuse. For example, organizations dedicated to developing programs and therapies designed for military personnel are gaining traction in the market. Collaborations between healthcare providers, researchers, and advocacy groups are essential to ensuring that the unique needs of diverse demographics are addressed effectively. By fostering partnerships and emphasizing patient-centric approaches, these companies can establish themselves as leaders in niche segments of the PTSD market and contribute to the overall advancement of mental health care.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 NeuroRx, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 H. Lundbeck A/S
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eli Lilly and Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Mindstrong Health, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Otsuka Pharmaceutical Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Post-traumatic Stress Disorder Market, By Application
    • 6.1.1 Military
    • 6.1.2 Veterans
    • 6.1.3 Emergency Services Personnel
    • 6.1.4 Survivors of Abuse
    • 6.1.5 Natural Disaster Survivors
  • 6.2 Post-traumatic Stress Disorder Market, By Product Type
    • 6.2.1 Medications
    • 6.2.2 Therapy
    • 6.2.3 Self-help Tools
    • 6.2.4 Apps
    • 6.2.5 Others
  • 6.3 Post-traumatic Stress Disorder Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Clinics
    • 6.3.3 Online Platforms
    • 6.3.4 Retail Pharmacies
    • 6.3.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Post-traumatic Stress Disorder Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Post-traumatic Stress Disorder market is categorized based on

By Product Type

• Medications
• Therapy
• Self-help Tools
• Apps
• Others

By Application

• Military
• Veterans
• Emergency Services Personnel
• Survivors of Abuse
• Natural Disaster Survivors

By Distribution Channel

• Hospitals
• Clinics
• Online Platforms
• Retail Pharmacies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Eli Lilly and Company
• Johnson & Johnson
• GlaxoSmithKline plc
• AbbVie Inc.
• Merck & Co., Inc.
• Boehringer Ingelheim
• AstraZeneca plc
• Otsuka Pharmaceutical Co., Ltd.
• H. Lundbeck A/S
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• NeuroRx, Inc.
• Mindstrong Health, Inc.